IVA (Inventiva) FFO


IVA Inventiva SA IVA
40 GF Score
Price $3.48
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva FFO?

FFO (Funds from operations) only applies to REITs.

IVA
40GF Score
Inventiva SA IVA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Inventiva (IVA) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.48 is trading 1188.9% above its estimated GF Value™ of $0.27. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVA:

  • FFO:
  • GF Value™: $0.27 vs. price of $3.48 (1188.9% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the IVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score

Get the complete analysis for IVA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.48
Price
$0.27
GF Value